The Effects of Platelet Rich Plasma Adjuvant to Type I/III Collagen Ratio, Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 in Pelvic Organ Prolapse Repair

Summary

The goal of this clinical trial is to analyze the effect of Platelet Rich Plasma (PRP) Adjuvant To Type I/III Colagen Ratio, MMP-2 and MMP-9 in Pelvic Organ Prolapse Repair.

The main questions it aims to answer are:

Does the PRP Adjuvant affect type I/III Colagen Ratio, MMP-2 and MMP-9 in Pelvic Organ Prolapse Repair? Researchers will compare patient who undergo prolapse surgery with PRP adjuvant versus patient who undergo prolapse surgery without PRP adjuvant (placeebo)

Participants will:

Patient will undergo pelvic organ prolapse reconstrucion surgery and punch biopsy and injection of PRP will perform in anterior vaginal mucosa at Pubocervical area. The second biopsy will attempt in 8 weeks post operative. imunohistochemistry examination will be done to compare the type I/III Colagen Ratio, MMP-2 and MMP-9 before and after surgery.

Conditions

• Pelvic Organ Prolapse Vaginal Surgery
• Platelet Rich Plasma Injection

Interventions

PROCEDURE

POP surgery and PRP injection

Patient who undergo POP surgery will receive PRP injection

PROCEDURE

POP surgery and placebo injection

patient who receive POP surgery and placebo injection

Sponsors & Collaborators

• Faculty of Medicine, Andalas University

  collaborator UNKNOWN

• Dr. M Djamil Hospital, Padang

  collaborator UNKNOWN

• Andalas University

  lead OTHER

Principal Investigators

• Yulia Margaretta Sari Yulia Margaretta, Sari, MD, MD · Biomedical Science Doctoral Programme Faculty of Medicine Andalas University/ Urogynecology Division Obstetrics and Gynecology Department M Djamil Hospital Padang Indonesia

• Aisyah Elliyanti, Prof, PhD, MD · Biomedical Science Doctoral Programme Faculty of Medicine Andalas University

• Bobby Indra, Utama, MD, PhD · Biomedical Science Doctoral Programme Faculty of Medicine Andalas University

• Zelly Dia, Rofinda, MD, PhD · Biomedical Science Doctoral Programme Faculty of Medicine Andalas University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

45 Years

Max Age

65 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-08-27

Primary Completion

2026-04-30

Completion

2026-08-31

Countries

• Indonesia

Study Locations